Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 245 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Jul 7, 2026, no change to tracked fieldsv244-v245
  2. Study sites revised (61)v243
  3. Study sites: 62 to 61v242
  4. Study sites: 63 to 62
    • Study completion date: Feb 22, 2026 to Feb 22, 2027
    v241
  5. Re-verified, no change to tracked fieldsv240
Show 44 earlier versionsHide 44 earlier versions
  1. Study sites revised (63)v239
  2. Study completion date: Feb 22, 2025 to Feb 22, 2026v238
  3. 2 versions Re-verified since Dec 3, 2024, no change to tracked fieldsv236-v237
  4. Study sites revised (63)v235
  5. 2 versions Re-verified since Jul 2, 2024, no change to tracked fieldsv233-v234
  6. Study sites revised (63)v232
  7. Study sites revised (63)v231
  8. Re-verified, no change to tracked fieldsv230
  9. Study completion date: Feb 22, 2025v229
  10. Re-verified, no change to tracked fieldsv228
  11. Study sites revised (63)v227
  12. 4 versions Re-verified since Nov 16, 2022, no change to tracked fieldsv223-v226
  13. Study sites revised (63)v222
  14. 4 versions Re-verified since Oct 23, 2021, no change to tracked fieldsv218-v221
  15. Study sites revised (63)v217
  16. 2 versions Re-verified since Jul 30, 2021, no change to tracked fieldsv215-v216
  17. Study sites: 62 to 63v214
  18. 7 versions Re-verified since Oct 14, 2020, no change to tracked fieldsv207-v213
  19. Study sites revised (62)v206
  20. Re-verified, no change to tracked fieldsv205
  21. Study sites revised (62)v204
  22. 2 versions Re-verified since Apr 11, 2020, no change to tracked fieldsv202-v203
  23. Study sites revised (62)v201
  24. 5 versions Re-verified since Nov 18, 2019, no change to tracked fieldsv196-v200
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, work in different ways to stop the growth of \[cancer/tumor\] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving more than one drug (combination chemotherapy) together with radiation therapy and bevacizumab may kill more tumor cells.
Trial Details
NCT Number NCT00334815
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Related terms Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov